At Senti Bio, we are developing therapies to fight the most challenging diseases. Our product candidate pipeline reflects how we are undertaking this battle —by using our gene circuit technology platform. 


Addressing Critical Unmet Needs in the Treatment of Acute Myeloid Leukemia (AML)

Senti Bio’s gene-circuit powered AML program may overcome key challenges posed by this devastating disease. We are driving toward a potential treatment for patients that does not rely on an invasive bone marrow transplant.

Precision-Targeted, Logic-Gated Immune Cells for Relapsed/Refractory AML

Leveraging the OR + NOT gate technology, Senti Bio’s multi-targeted, logic-gated allogeneic CAR-NK cell product candidate, SENTI-202, is designed to broadly target heterogeneous AML cells, including critical leukemic stem cells that promote cancer relapse, while preventing damage to healthy blood stem cells.


Offering a Transformative New Approach for the Treatment of Hepatocellular Carcinoma (HCC)

Senti Bio’s gene circuit-powered allogeneic CAR-NK cells are programmed to overcome the suppressive tumor microenvironment, and offer a more effective and safer treatment option for people with HCC.

Armored Immune Cells for Relapsed/Refractory Advanced HCC

Using gene circuits that express combinatorial immune effector payloads, Senti Bio’s allogeneic CAR NK cell product candidate, SENTI-301, drives enhanced NK cell activity and remodeling of the tumor microenvironment to promote anti-tumor efficacy. Senti’s synthetic biology platform enables optimized expression of multiple payloads and the ability to regulate payloads to optimize therapeutic efficacy and safety.